Matricelf

Asaf Toker, M.D., CEO

April 21 | 2:30pm | Gaudi 3 Ballroom

Ness Ziona, Israel

(NASDAQ: MTLF)

In-Person Presentation

Matricelf is a biotechnology company in the field of tissue engineering. The company develops a platform for autologous 3D printing of tissues and organs that significantly reduce the risk of implant rejection. Using a single biopsy from the patient we develop tissues that we can 3D print, inject or simply place where needed. In 2019, we printed, for the first time in human history, a three-dimensional human heart from human tissue. The company completed successful pre-clinical studies in a number of medical conditions and our first indication is Spinal Cord Injury. Considering the fact that SCI patients have no suggested treatments and are expected to spend their life in a wheelchair motivated us to further develop the technology and specifically SCI implant. In our pre-clinical animal studies, mice treated with our implants regained their walking ability both in acute and chronic spinal cord injury models.

www.matricelf.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions